Algocalmin (metamizole) is commonly used to help with symptomatic relief, addressing symptoms that create noticeable physiological strain or interfere with daily functioning. As part of supportive symptom management, Algocalmin is applied when pain or fever symptoms require specific attention. This is consistent with its established use in various countries.

---

Management of Severe Acute Pain

This medicine is applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort, such as pain following injuries (post-traumatic) or surgical procedures (post-operative). It helps address symptom clusters that may become intense or disruptive, providing supportive relief when symptoms become temporarily overwhelming.

---

Relief from Spasmodic or Colic Pain

Algocalmin is relevant in contexts marked by increased discomfort or tension, specifically for addressing symptoms related to heightened physiological activity, such as painful colic. This applies to conditions involving episodic or fluctuating manifestations, like biliary or renal colic, supporting the patient during difficult episodes by easing distress.

---

Reduction of High, Refractory Fever

It is used in situations involving certain distressing symptoms like a high body temperature (fever), particularly when the fever is considered refractory (unresponsive to other standard fever-reducing measures). This is applied in scenarios where additional management of discomfort is required, contributing to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Relevant for Symptomatic Management of Severe Pain & Colic

Algocalmin (metamizole) eligibility is strictly defined by regulatory authorities based on a patient's medical history and physiological status.

Contraindicated Populations

Use is prohibited in patients with a history of agranulocytosis or impaired bone marrow function, or diseases of the hematopoietic system. The medicine is also strictly contraindicated in patients with known analgesic-induced asthma syndrome or severe pyrazolone hypersensitivity. It must not be used during the third trimester of pregnancy due to risks to the fetus.

---

Age and Physiological Restrictions

Standard eligibility is established for adults and adolescents aged 15 years and older (or ge 53 kg). It is contraindicated in infants below the age of 3 months or weighing less than 5 kg. For the elderly population, a dose reduction is required. Patients with renal or hepatic impairment are restricted from taking multiple high doses. Use during lactation is generally not recommended, and if a single dose is administered, regulatory authorities advise discarding breast milk for a 48-hour period. Caution is also noted for patients with pre-existing hypotension or unstable circulation.

Algocalmin Interactions with other medicines and products

Official regulatory information for Sodium Metamizole (Algocalmin) documents several clinically significant drug-drug interactions, primarily classified as pharmacokinetic (metabolic) and pharmacodynamic.

Pharmacokinetic Interactions (Exposure Modification)

Metamizole is documented to be a moderate-to-strong inducer of specific liver enzymes, including CYP3A4, CYP2B6, and CYP2C19, and a moderate inhibitor of CYP1A2. This enzyme modulation results in a reduction of plasma concentrations (systemic exposure) for several co-administered drugs that are sensitive substrates of these enzymes, including:

• Bupropion
• Efavirenz
• Methadone
• Ciclosporin
• Tacrolimus
• Sertraline
• Quetiapine

This outcome signifies a potential decrease in the clinical effectiveness of these interacting medicines.

Pharmacodynamic Interactions and Timing Rules

Interacting Substance	Official PD Interaction	Regulatory Requirement
Acetylsalicylic acid (low-dose for cardioprotection)	Inhibition of the antiplatelet effect.	Mandatory separation of administration timing is required.
Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Additive risk of Nephrotoxicity (kidney function risk).	Co-administration is generally advised with caution due to additive risks.

Interaction-Related Restrictions (Contraindicated Combinations)

Formal restrictions specified in regulatory labeling include the prohibition of use in patients with a prior history of Agranulocytosis due to pyrazolone derivatives or in patients with Impaired Bone Marrow Function. Additionally, the drug is formally contraindicated in specific populations, including Infants below 3 months or 5 kg body weight and during the Third Trimester of Pregnancy.

Algocalmin, whose active substance is metamizole (also known as dipyrone), works through a complex, multifaceted mechanism primarily acting within the central nervous system (CNS) to modulate peripheral and central signaling involved in afferent processing and smooth muscle activity.

---

Modulating Prostaglandin Synthesis in the CNS

The drug's active metabolites engage mechanisms that involve the cyclooxygenase (COX) enzyme system, particularly the COX-3 variant found predominantly in the brain and spinal cord. By inhibiting this enzyme, Algocalmin modifies early molecular steps that regulate the production of prostaglandins, like PGE2, in the CNS. This modulates downstream signaling by reducing the concentration of PGE2 at the target site.

---

Central Pathway Engagement for Analgesia

Algocalmin's metabolites are known to act within domains involving receptor- or enzyme-mediated signaling beyond the COX system. They initiate signaling sequences that include the activation of the endogenous opioidergic and cannabinoid systems in the descending pain-modulation pathways. This dual engagement influences descending pain modulation pathways by altering activity within both opioidergic and cannabinoid signaling cascades.

---

Smooth Muscle Tone Regulation

Algocalmin is unique among common analgesics for its effect on smooth muscle contractility. It engages mechanisms that regulate overactive or dysregulated processes within smooth muscle cells. The drug and its metabolites affect systems where specific transmitters or mediators dominate, notably by inhibiting the release of intracellular Ca^2+ (calcium ions) by reducing inositol phosphate synthesis. This action results in reduced intracellular Ca^2+ availability, inducing relaxation in smooth muscle tissues.

How Algocalmin (Metamizole) Is Used: Official Administration Guidelines

Metamizole administration follows a standardized protocol for the short-term management of acute severe symptoms. This approach utilizes a variety of dosage forms and specific frequency patterns to manage total daily exposure.

---

Approved Routes and Dosing

Metamizole is approved for use via oral (tablets or drops), rectal (suppositories), and parenteral (Intravenous or Intramuscular) routes. The maximum daily doses are strictly defined to prevent excessive exposure.

Administration Route	Maximum Adult Single Dose	Maximum Adult Daily Dose
Oral	1,000 mg	4,000 mg
Parenteral (IV/IM)	1,000 mg	5,000 mg

---

Dosing Frequency and Special Conditions

Official instructions mandate that the lowest dose required be selected for treatment. Oral and parenteral doses may be repeated up to four times daily, maintaining a minimum interval of six to eight hours between administrations. Rectal administration may be repeated up to six times daily, with an interval of four to eight hours.

Population-Specific Rules: Dosing for pediatric patients (up to 14 years) is calculated based on body weight (typically 8–16 mg/kg). The medicine is contraindicated for infants under three months of age or those weighing less than 5 kg.

Parenteral Technique: Intravenous injection requires specific procedural compliance: the solution must be administered very slowly, not exceeding 1 ml per minute, with the patient in a supine position.

Research Evidence / Overview of Studies for Algocalmin (Sodium Metamizole)

This section provides an overview of the official research, including clinical trials and scientific reviews, that has explored the uses of Algocalmin (Sodium Metamizole). This is a strictly descriptive summary of the study landscape, not a guide for treatment or use.

---

Evidence for Use in Acute Severe Pain

Research has primarily focused on the use of this medication in contexts involving acute, severe physical discomfort, such as pain associated with specific events following surgical procedures. The core evidence was evaluated in short-term, randomized controlled trials (RCTs) and systematic reviews. These studies were designed to monitor symptom intensity over short, defined intervals, tracking the required use of rescue analgesic medication.

Studies explored patterns where the use of this medication coincided with measurements of supplementary opioid pain medication used were tracked relative to placebo. Findings reported observations of outcomes measured by 'Total Pain Relief' (TOTPAR) metrics in the studied population, though specific results varied by dose and study design. The evidence contributes to the broader evidence landscape by providing insight into short-term changes in pain intensity.

However, existing studies provide limited information regarding the durability of symptom improvement. Follow-up durations were typically limited to the first few hours or days after treatment. Comparative evidence is lacking against the full range of other active treatments, and evidence quality varies across studies.

---

Research on Spasmodic and Colic Pain

Algocalmin was studied for its use in managing acute symptoms related to spasmodic or colic pain, conditions characterized by fluctuating or episodic manifestations, such as renal or biliary colic. Research explored these acute scenarios using randomized controlled trials, focusing on single-dose administration during periods where symptoms were noticeable. Studies monitored the monitored use of supplementary pain medication during these acute episodes.

The data for this use is often specific to the initial treatment of an acute, disruptive episode. Follow-up durations were limited to the immediate post-administration period, meaning long-term outcomes related to the evolution of the condition are not fully established. Additionally, comparative evidence is lacking across different pharmaceutical forms in the systematic research.

Common questions about Algocalmin (FAQ)

Q: Does Algocalmin require a doctor's prescription, or can I buy it over the counter?

According to official regulatory documents, Algocalmin is generally designated as a prescription-only medicine (POM). Official guidance indicates that authorization from a healthcare professional is typically required before the medicine can be dispensed.

---

Q: What is the active ingredient in Algocalmin?

The active substance in Algocalmin is metamizole sodium. This active substance is recognized for its effects on pain relief and fever reduction, which is its primary function.

---

Q: Is Algocalmin safe to take during pregnancy?

Regulatory sources generally advise against the use of Algocalmin during the first and third trimesters of pregnancy. Official product information suggests that use during the second trimester requires careful assessment and recommendation from a healthcare provider. Patients who are pregnant or planning to become pregnant should rely on a healthcare professional's advice regarding this medication.

---

Q: Is Algocalmin used for pain, fever, or both?

Official product information indicates that Algocalmin is indicated for the management of severe pain and high fever. It is used in situations where other treatments may be contraindicated or have not provided sufficient relief.

---

Q: Can I take Algocalmin if I am breastfeeding?

The official product information advises that Algocalmin should generally not be used while breastfeeding. The medicine's components pass into breast milk, and official information advises against its use due to potential risk to the infant.

Official Storage and Disposal Instructions for Algocalmin (Metamizole Sodium)

Algocalmin must be stored under specific environmental conditions to maintain the stability of the active ingredient, Metamizole Sodium, as defined in official regulatory labeling.

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C or 30 C (controlled room temperature).
Protection	Must be kept in the original container, protected from light, and stored in a dry place.
Handling	Do not freeze the product. The container must be kept tightly closed.
Child Safety	Must be stored strictly out of the sight and reach of children.

Disposal Requirements

Unused or expired Algocalmin must be discarded according to established pharmaceutical waste protocols. The product must not be thrown into household trash or disposed of via wastewater (sink or toilet). Disposal must be carried out according to local or national regulations, often by returning the medicine to a pharmacy or using an official drug take-back scheme.